首页> 外文期刊>Angiology: the Journal of Vascular Diseases >Intravenous hydroxyethylrutosides combined with long-term oral anticoagulation in atherosclerotic nonreconstructable critical leg ischemia: a retrospective study.
【24h】

Intravenous hydroxyethylrutosides combined with long-term oral anticoagulation in atherosclerotic nonreconstructable critical leg ischemia: a retrospective study.

机译:静脉羟乙基芸苔苷联合长期口服抗凝治疗动脉粥样硬化不可重建的严重下肢缺血:一项回顾性研究。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: To evaluate in a group of seriously diseased patients with nonreconstructable chronic critical leg ischemia (CLI), treated by a combination of i.v. hydroxyethylrutosides (HR)* and oral anticoagulation (AC) by warfarin, the short-term effects on the cutaneous microvascular blood perfusion of the soles of feet and especially the long-term clinical outcome in terms of amputation and death. DESIGN: A retrospective comparison between two groups of patients, HR + AC and a comparable reference group, fulfilling the same inclusion and exclusion criteria corresponding to the definition of CLI according to the Second European Consensus Document (1991). Clinical follow-up in both groups was made after 1, 3, 6, 12, and 24 months. SETTING: Patients were examined at university departments of clinical physiology with special interest in peripheral vascular disease, in cooperation with colleagues at university departments of surgery, internal medicine and dermatology of Karolinska Hospital, Sodersjukhuset and Huddinge Hospital. PATIENTS: A total of seventy patients with CLI according to the definition of the Second European Consensus Document, 1991, ie, besides severe rest pain or ischemic lesions also a toe blood pressure < 30 mg Hg. Group with HR + anticoagulation (AC): 42 patients (19 diabetics, 23 nondiabetics). Reference group: 28 patients (18 diabetics, 10 nondiabetics). For distribution of age and toe blood pressure at baseline, see Table I. INTERVENTIONS: Therapy group: besides ordinary standard therapy, daily HR infusions for a mean period of 3.6 weeks + oral anticoagulation continued to the end of the study at 24 months. A comparable reference group on the same basic therapy but without the combination HR + AC. PARAMETERS IN EVALUATION: Short-term parameters: clinical data, skin temperature, and fluorescein imaging. Long-term outcome: amputation or death. RESULTS: Short-term and long-term results with HR + AC indicated that patients with severe CLI and very poor prognosis benefited in terms of survival and limb salvage from initial therapy with HR infusion combined with long-term oral anticoagulation. Results of this combined treatment seem at least comparable with those with i.v. prostacyclin analogies.
机译:目的:评估一组重症患者,这些患者通过静脉内注射联合治疗无法治愈的慢性严重下肢缺血(CLI)。华法林对羟乙基芸苔苷(HR)*和口服抗凝(AC)的影响,对脚底皮肤微血管血液灌注的短期影响,尤其是在截肢和死亡方面的长期临床结果。设计:回顾性比较两组患者,HR + AC和可比较的参考组,符合第二欧洲共识文件(1991)的相同的纳入和排除标准,与CLI的定义相对应。两组均在1、3、6、12和24个月后进行临床随访。地点:与大学外科,卡罗林斯卡医院,Sodersjukhuset和Huddinge医院的内科和皮肤病学部门的同事合作,在大学临床生理学部门对周围血管疾病特别感兴趣的患者进行了检查。患者:根据1991年第二次欧洲共识文件的定义,共有70例CLI患者,即,除了严重的静息疼痛或局部缺血性病变外,脚趾血压<30 mg Hg。 HR +抗凝(AC)组:42例(糖尿病19例,非糖尿病23例)。参考组:28例(糖尿病患者18例,非糖尿病患者10例)。有关基线时的年龄和脚趾血压的分布,请参阅表I。干预:治疗组:除普通标准治疗外,每天HR输注平均3.6周+口服抗凝治疗持续到研究结束24个月。具有相同基本疗法但没有HR + AC组合的类似参考组。评估参数:短期参数:临床数据,皮肤温度和荧光素成像。长期结果:截肢或死亡。结果:HR + AC的短期和长期结果表明,严重的CLI和预后很差的患者从HR输注结合长期口服抗凝治疗的初始治疗中可以改善生存率和挽救肢体。这种联合治疗的结果似乎至少与静脉注射的结果相当。前列环素类比。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号